This is where the BEATsepsis project comes in. Up to 40 percent of patients who have experienced sepsis are re-hospitalised within a year, often suffering from neurological problems, muscle damage, or recurring infections. Eleven European partner institutions, including LBI Trauma, are working together to better understand the mechanisms behind these late effects. Among other approaches, researchers are aiming to identify biological markers that can make the risk of complications visible and allow for more targeted follow-up care.

In our new World Sepsis Day video, science communicator Conny Schneider speaks with Marcin Osuchowski, head of the Sepsis-Trauma-Shock research group at LBI Trauma. His team uses the so-called Luminex technology to measure up to 100 markers in patients’ blood – not only during the acute phase in intensive care, but also weeks after discharge. This makes it possible to track the course of recovery and alert physicians as well as patients early on to possible complications.

At the heart of BEATsepsis lies the understanding that sepsis is not only about survival, but also about whether patients can find their way back to a stable, healthy life. At LBI Trauma, we are proud to be part of the BEATsepsis puzzle and to advance research that improves quality of life after sepsis. More information on the project can be found here.